Drug delivery · 2017
Marked augmentation of PLGA nanoparticle-induced metabolically beneficial impact of γ-oryzanol on fuel dyshomeostasis in genetically obese-diabetic ob/ob mice.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kozuka Chisayo, Shimizu-Okabe Chigusa, Takayama Chitoshi, Nakano Kaku, Morinaga Hidetaka, Kinjo Ayano, Fukuda Kotaro, Kamei Asuka, Yasuoka Akihito, Kondo Takashi, Abe Keiko, Egashira Kensuke, Masuzaki Hiroaki
Аннотация
Our previous works demonstrated that brown rice-specific bioactive substance, γ-oryzanol acts as a chaperone, attenuates exaggerated endoplasmic reticulum (ER) stress in brain hypothalamus and pancreatic islets, thereby ameliorating metabolic derangement in high fat diet (HFD)-induced obese diabetic mice. However, extremely low absorption efficiency from intestine of γ-oryzanol is a tough obstacle for the clinical application. Therefore, in this study, to overcome extremely low bioavailability of γ-oryzanol with super-high lipophilicity, we encapsulated γ-oryzanol in polymer poly (DL-lactide-co-glycolide) (PLGA) nanoparticles (Nano-Orz), and evaluated its metabolically beneficial impact in genetically obese-diabetic ob/ob mice, the best-known severest diabetic model in mice. To our surprise, Nano-Orz markedly ameliorated fuel metabolism with an unexpected magnitude (∼1000-fold lower dose) compared with regular γ-oryzanol. Furthermore, such a conspicuous impact was achievable by its administration once every 2 weeks. Besides the excellent impact on dysfunction of hypothalamus and pancreatic islets, Nano-Orz markedly decreased ER stress and inflammation in liver and adipose tissue. Collectively, nanotechnology-based developments of functional foods oriented toward γ-oryzanol shed light on the novel approach for the treatment of a variety of metabolic diseases in humans.
Предметные рубрики MeSH
Administration, OralAnimalsBehavior, AnimalBlood GlucoseDiabetes MellitusDisease Models, AnimalDose-Response Relationship, DrugDrug Administration ScheduleDrug CarriersDrug CompoundingEndoplasmic Reticulum StressEnergy MetabolismFood PreferencesGastrointestinal MicrobiomeHypoglycemic AgentsHypolipidemic AgentsInsulin ResistanceIntestinal AbsorptionIslets of LangerhansLactic AcidLipidsLiverMaleMice, ObeseNanomedicineNanoparticlesObesityPhenylpropionatesPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerSolubilityTechnology, PharmaceuticalTime Factors